Vincent Y. See, MD

Education

1993 – 1997    S.B.     Massachusetts Institute of Technology, (biology)

1997 – 2001    M.D.    University of Pennsylvania School of Medicine

Post Graduate Education and Training

Internships & Residencies

2001 – 2002    Intern               Medicine         Hospital of the University of Pennsylvania

2002 – 2004    Resident           Medicine         Hospital of the University of Pennsylvania

Fellowships

2004 – 2007    Clinical Fellow            Cardiovascular Medicine         Boston Medical Center

2004 – 2007    Teaching Fellow          Medicine                               Boston University

2006 – 2008    Research Fellow          Genetics                               Harvard Medical School

2006 – 2007    Research Fellow          Cardiovascular Medicine         Brigham & Women’s Hospital

2007 – 2009    Clinical Fellow             Cardiac Electrophysiology       Brigham & Women’s Hospital

Clinical Activities

My cardiac electrophysiology practice is based at the University of Maryland Medical Center in Baltimore, MD.  My practice is comprehensive of all available cardiac electrophysiology services including consultation, diagnostic electrophysiology studies, implantable device / lead management, and interventional electrophysiology.   Interventional electrophysiology procedures that are performed are comprehensive and include catheter ablation of supraventricular tachycardia, atrial fibrillation, and ventricular tachycardia by both endocardial and epicardial approaches.  Cardiac device and lead management services include implantation and extraction of cardiac pacing, defibrillation, and resynchronization devices.  I lead the quality assurance program within the Cardiac Electrophysiology Laboratory.  Other clinical contributions include attending on the inpatient cardiovascular services at the University of Maryland Medical Center and Veterans Affairs Health System – Baltimore.  I co-founded and co-direct a collaborative Cardiovascular Genetics Clinic at the University of Maryland with an interest in evaluating patients and families with inherited arrhythmia and cardiovascular disorders.  I co-founded a left atrial appendage occlusion program in collaboration with interventional cardiology and cardiac surgery colleagues using the Watchman, Lariat, and AtriClip devices.  This left atrial appendage program has now developed into the UMMC Program in Atrial Fibrillation, for which I serve as Medical Director.  The Program in Atrial Fibrillation is developing personalized medicine programs to risk stratify atrial fibrillation at diagnosis and ablation.  Through this program, we continue to expand our LA appendage, hybrid surgical-endocardial ablation, and comprehensive atrial fibrillation services. 

Research Activities

Our research is focused on examining how circulating biomarkers of cardiac fibrosis, myocardial injury, and cardiometabolic disease may influence outcomes in cardiac arrhythmia ablation procedures.  We are also examining how these biomarkers may be integrated with other molecular and imaging markers to better understand arrhythmia mechanisms and prognosis.  We are extending our prior work with atrial fibrillation to ventricular tachycardia and left atrial appendage occlusion procedures.  Additional interests include sudden cardiac death risk in heart failure populations with resolved left ventricular dysfunction.  Collaborations include studies of the clinical utility of genetic testing in long QT syndrome, additional phenotyping of cardiomyopathy and inherited arrhythmia syndrome patients who have already undergone genetic testing, and characterization of a population with a channelopathy variant.  We are also working with the cardiovascular pharmacy group to model clinical utilization of different forms of anti-arrhythmic drugs. 

atrial fibrillation, ventricular tachycardia, ablation, left atrial appendage occlusion, lead extraction, inherited arrhythmias, epicardial ablation, biomarkers, cardiac fibrosis

Husain M, Jiang L, See V, Bein K, Simons M, Alper SL, Rosenberg RD. Regulation of vascular smooth muscle cell proliferation by plasma membrane calcium ATPase.  Am J Physiol.  1997; 272:(Cell Physiol. 41): C1947-C1959

Mainigi SK, Goldberg LR, Sasseen BM, See VY, Wilensky RL. Relative contributions of intimal hyperplasia and vascular remodeling in early cardiac transplant mediated coronary artery disease.  Am J Cardiol. 2003; 91(3): 293-6

See VY, DeNofrio D, Goldberg LR, Chang G, Sasseen BM, Kolansky DM, Pickering F, Kao A, Loh E, Wilensky RL. Atorvastatin eliminates the post-cardiac transplant increase in LDL, reduces development of intimal hyperplasia, and ameliorates progression of endothelial dysfunction.  Am J Cardiol. 2003; 92: 11-15 

Herrmann HC, Silvestry FE, Glaser R, See V, Kasner S, Bradbury D, Chang G, Hirshfeld JW, Horwitz PA, Kelley M. Percutaneous patent foramen ovale and atrial septal defect closure in adults: Results and device comparison in 100 consecutive implants at a single center.   Catheterization and Cardiovascular Interventions.  2005; 64(2): 197-203

Wolf CM, Wang L, Alcalai R, Pizard A, Burgon PG, Ahmad F, Sherwood M, Branco DM, Wakimoto H, Fishman GI, See V, Stewart CL, Conner DA, Berul CI, Seidman CE, Seidman JG.  Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction disease.  J Mol Cell Card.  2008; 44(2): 293-303

See VY, Roberts-Thomson K, Stevenson WG, Camp PC, Koplan BA.  Atrial arrhythmias following lung transplantation: Epidemiology, Mechanisms at Electrophysiology Study, and Outcomes.  Circ Arrhythm Electrophysiol.  2009; 2(5): 504-510 

Beck H and See VY.  Acute management of atrial fibrillation: from emergency department to cardiac care unit.  Cardiol Clin.  2012; 30(4): 567-589

Remo BF, Beck H, See V, Saliaris A, Shorofsky S, Dickfeld T.  First US case of a transformer break with loss of shock therapy and rapid battery depletion in the Boston Scientific INCEPTA ICD.  J Innov in Cardiac Rhythm Management.  2013; 4: 1246-1247

Hussein AA, Gottdiener JS, Bartz TM, Sotoodehnia N, Defilippi C, See V, Deo R, Siscovick D, Stein PK, Lloyd-Jones D.  Inflammation and sudden cardiac death in a community-based population of older adults: The Cardiovascular Health Study.  Heart Rhythm.  2013; 10(10): 1425-1432

Ahmad G, Hussein AA, Mesubi O, Tian J, Ferieg H, Elmaaty MA, Hamdy A, Ego-Osuala K, Jimenez A, See V, Saliaris A, Shorofsky S, Dickfeld T.  Impact of fluoroscopy unit on the accuracy of a magnet-based electroanatomic mapping and navigation system: an in vitro and in vivo validation study. Pacing Clin Electrophysiol.  2014; 37(2): 157-163

Hussein AA, Jimenez A, Ahmad G, Mesubi O, Klein T, Gurm G, Beck H, Shams O, See V, Saliaris A, Shorofsky S, Dickfeld T.  Assessment of ventricular tachycardia scar substrate by intracardiac echocardiography.  Pacing Clin Electrophysiol.  2014; 37(4): 412-421

Hussein AA, Abutaleb A, Jeudy J, Phelan T, Patel R, Shkullaku M, Siddiqi F, See V, Saliaris A, Shorofsky SR, Dickfeld T.  Safety of computed tomography in patients with cardiac rhythm management devices: assessment of the U.S. Food and Drug Administration advisory in clinical practice.  J Am Coll Cardiol.  2014; 63(17): 1769-1775

Mesubi O, Ahmad G, Jeudy J, Jimenez A, Kuk R, Saliaris A, See V, Shorofsky S, Dickfeld T.  Impact of ICD artifact burden on late gadolinium enhancement cardiac MR imaging in patients undergoing ventricular tachycardia ablation.  Pacing Clin Electrophysiol.  2014; 37(10): 1274-1283

Mesubi O, Ego-Osuala K, Jeudy J, Purtilo J, Synowski S, Abutaleb A, Niekoop M, Abdulghani M, Asoglu R, See V, Saliaris A, Shorofsky S, Dickfeld T.  Differences in quantitative assessment of myocardial scar and gray zone by LGE-CMR imaging using established gray zone protocols.  Int J Cardiovasc Imaging. 2015 Feb;31(2):359-68

Klein T, Abdulghani M, Smith M, Huang R, Asoglu R, Remo BF, Turgeman A, Mesubi O, Sidhu S, Synowski S, Saliaris A, See V, Shorofsky S, Chen W, Dilsizian V, Dickfeld T.  Three-Dimensional 123I-Meta-Iodobenzylguanidine Cardiac Innervation Maps to Assess Substrate and Successful Ablation Sites for Ventricular Tachycardia: A Feasibility Study for a Novel Paradigm of Innervation Imaging.  Circ Arrhythm Electrophysiol.  2015; 8(3): 583-91.          

Abdulghani M, Duell J, Smith M, Chen W, Bentzen SM, Asoglu R, Klein T, Bob-Manuel T, Saliaris A, See V, Shorofsky S, Dilsizian V, Dickfeld T.  Global and Regional Myocardial Innervation Before and After Ablation of Drug-Refractory Ventricular Tachycardia Assessed with 123I-MIBG.  J Nucl Med. 2015; 56 Suppl 4:52S-58S.

Srivastava MC, See VY, Dawood MY, Price MJ.  A review of the LARIAT device: insights from the cumulative clinical experience.  Springerplus. 2015; 17;4:522

Srivastava MC, See VY.  The Lariat for left atrial appendage closure: rehash of known literature or a true analysis?  JAMA Intern Med. 2015; 175(11): 1868-9

Hussein AA, Niekoop M, Dilsizian V, Ghzally Y, Abdulghani M, Asoglu R, Chen W, Smith M, See V, Shorofsky SR, Dickfeld TM.  Hibernating substrate of ventricular tachycardia: a three-dimensional metabolic and electro-anatomic assessment.  J Interv Card Electrophysiol. 2017; 48(3): 247-254.  PMID 28120237

Sourwine M, Jeudy J, Miller B, Vunnam R, Imanli H, Mesubi O, Etienne-Mesubi M, See V, Shorofsky S, Dickfeld T.  Location, variations and predictors of epicardial fat mapping using multi-detector computed tomography to assist epicardial ventricular tachycardia ablation.  Pacing Clin Electrophysiol.  2017; doi: 10.1111/pace.13119 [Epub ahead of print].  PMID 28722134

See VY.  Organized atrial arrhythmias after cardiac transplantation – the overlooked value of the 12-lead electrocardiogram and cavotricuspid atrial flutter isthmus.  J Heart Lung Transplant.  In Press.  10.1016/j.healun.2017.10.018